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The European Society of Cardiology Congress 2018 of-
fered many interesting presentations of the results of 
large clinical trials. Doctors as well as nurses and medical 
technicians had the opportunity to become acquainted 
with many reports that will affect daily clinical practice 
and treatment of patients. In this paper, we offer you 
a subjective review of the most interesting and valuable 
reports in the field of invasive cardiology.
The results of one-year follow-up of patients included 
in the CULPRIT-SHOCK trial are of great practical impor-
tance. This trial evaluated clinical outcomes in patients 
with acute myocardial infarction and cardiogenic shock 
qualified for immediate multivessel percutaneous coro-
nary intervention (PCI) compared with culprit-lesion-only 
PCI [1]. The inclusion criteria were: myocardial infarction, 
cardiogenic shock and hemodynamically significant lesions 
in at least two coronary arteries. A significant lesion was 
defined as a stenosis greater than 70% in a vessel with 
a diameter of more than 2 mm. Exclusion criteria included: 
resuscitation longer than 30 minutes, symptoms of the 
central nervous system (CNS) injury, shock occurrence 
earlier than 12 hours prior to admission, severe renal 
failure (glomerular filtration rate [GFR] < 30 mL/min). 
Patients were randomly assigned to one of two equal 
groups: a culprit-only PCI group and an immediate mul-
tivessel PCI group (in which complete revascularization 
of all significant lesions was performed). The primary 
endpoint included death from any cause or severe renal 
failure leading to renal replacement therapy at 30 days, 
while the secondary endpoint included death from any 
cause, renal replacement therapy, recurrent myocardial 
infarction, repeat revascularization and hospitalization 
for heart failure in one-year follow-up. The results of the 
trial showed that at 30 days the mortality rate in the 
culprit-lesion-only PCI group was 45.9%, while in patients 
who underwent multivessel revascularization it was 55.4% 
(a significant difference in favor of the culprit-vessel-only 
strategy, p = 0.01). In the 12-month follow-up the risk of 
death was not significantly different between groups, al-
though death from any cause occurred 12% less frequently 
– in 50% of patients who underwent culprit-vessel-only 
PCI and in 56.9% of patients who underwent multivessel 
revascularization (relative risk [RR] 0.88; 95% confidence 
interval [CI] 0.76–1.01). Recurrent myocardial infarction 
occurred in 1.7% of patients in the culprit-lesion-only PCI 
group and in 2.1% of patients who underwent complete 
revascularization — there was no significant difference 
between groups (RR 0.85; 95% CI 0.29–2.5). As predic-
ted, the need for repeat revascularization was observed 
significantly more common in the culprit-lesion-only PCI 
group than in the immediate multivessel revascularization 
group (32.3 vs 9.4%; RR 3.44; 95% CI 2.39–4,95) as well 
as rehospitalization due to heart failure (5.2 vs 1.2%; 
RR 4.46; 95% CI 1.53–13.04). The study confirmed that 
in patients with myocardial infarction and cardiogenic 
shock the risk of death or renal replacement therapy was 
lower with culprit-lesion-only PCI compared to multivessel 
revascularization, and in one-year follow-up there was no 
significant differences in mortality rate between the two 
groups. The CULPRIT-SCHOCK trial therefore confirms 
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tion, decreased ejection fraction (15% < EF < 40%) and 
symptoms of heart failure. Severe secondary mitral regurgi-
tation was defined as the effective regurgitant orifice (ERO) 
> 20 mm2 and regurgitant volume > 30 mL. Patients were 
randomized in a 1:1 ratio to percutaneous mitral valve 
regurgitation repair (152 patients) or pharmacological 
treatment (152 patients). The composite endpoint inclu-
ded death from any cause or hospitalization due to heart 
failure at 12 months. In the group treated with MitraClip, 
the composite end-point occurred in 54.6% of patients, 
and in the group receiving conservative treatment — in 
51.3% of patients (OR 1.16, 95% CI 0.73–1.84, p = 0.53). 
All-cause mortality rate was 24.3% in the invasively treated 
group and 22.4% in the conservatively treated group (OR 
1.11, 95% CI 0.69–1.77). Similarly, there were no signi-
ficant differences in unscheduled hospitalizations due to 
heart failure symptoms: 48.7% in the intervention group 
compared to 47.4% in the conservatively treated group. The 
presented results suggest the lack of benefits in terms of 
improved survival or decreased frequency of unplanned 
hospitalization for heart failure in patients with severe 
mitral regurgitation treated with MitraClip vs pharmacolo-
gical treatment in the 12-month follow-up. Similarly, in the 
aspect of the New York Heart Association (NYHA) functional 
class, despite significant improvement in both groups at 
12 months, there were no statistically significant differen-
ces between pharmacological vs invasive treatment with 
MitraClip device. These findings are in apparent contra-
diction with the results of the US COAPT, announced a few 
weeks later, which showed the excellent effectiveness of 
secondary mitral regurgitation repair with MitraClip devi-
ce in a similar (though non-identical) patient population, 
including a reduction in overall mortality. A comparison of 
these trials provides instructive conclusions. The reasons 
for MITRA-FR failure may be a relatively low technical 
success rate of the procedure, its 3-fold lower durability 
and more frequent complications (14.6% vs 8.5% in the 
COAPT study). The limitation of the study was the lack of 
standardization of pharmacological treatment before the 
procedure — only COAPT assumed the maximum tolerated 
therapy in both therapeutic arms; drug therapy was also 
more stable during COAPT. Importantly, MITRA-FR patients 
had less severe mitral regurgitation (ERO = 31 ± 10 mm2 vs 
41 ± 15 mm2 in COAPT) with more advanced heart failure-
-related remodeling (left ventricular end-diastolic volume 
[LVEDV] higher by 1/3). In the light of the unambiguous 
efficacy of MitraClip therapy demonstrated in COAPT, the 
MITRA-FR study rather provides information which errors 
in the qualification of patients should be avoided, with 
particular emphasis on the role of precise quantitative as-
sessment of mitral regurgitation, which plays a key role in 
the clinical status of a qualified patient. The inconsistency 
between the results of the MITRA-FR and COAPT emphasize 
the need for further research aimed at optimally identify-
that mortality is still very high in patients with myocardial 
infarction and cardiogenic shock, but revascularization 
limited to the culprit vessel seems to be more favorable.
The Canadian Spontaneous Coronary Artery Dissection 
(SCAD) Cohort Study explored a poorly understood but 
clinically significant problem of spontaneous dissection 
of coronary arteries [2]. This mechanism is responsible 
for up to 24% of myocardial infarctions, mainly in women 
before the age of 50. The Canadian multicenter register 
is the largest in the world to date. The main aim of the 
study was to improve understanding of SCAD, and the 
secondary aim was to assess treatment strategies. The 
study included 804 patients. Mean age was 52 years, 
and women accounted for 88.5% of the study group, of 
which 55% were in the postmenopausal age. ST-segment 
elevation myocardial infarction (STEMI) was diagnosed in 
29.7% of patients, non-ST-segment elevation myocardial 
infarction (NSTEMI) — in 69.9%. Lesions responsible for 
acute coronary syndrome (ACS) occurred mainly in left 
anterior descending (60%) and circumflex artery (38%). In 
60% of patients, SCAD appeared as diffuse and smooth 
stenosis. Physical effort was a triggering factor in 29% 
of patients, and severe stress in as many as 50% of pa-
tients. The SCAD study confirmed that in 31.1% of patient 
a predisposing factor was fibro-muscular dysplasia (FMD), 
a non-inflammatory vascular disease that not only affects 
renal and cervical vessels, but also is a significant problem 
in the aspect of spontaneous coronary dissection.
In the SCAD study population, PCI was performed only 
in 12% of patients, of which as many as 30% of cases 
were unsuccessful and 41% — suboptimal. However, the 
30-day mortality rate was only 0.1%. The mean follow-up 
period was 3.1 years and during this time, the risk of 
death was 1.2%, recurrent myocardial-infarction occurred 
in 4.8% of patients and 1.5% required unplanned repeat 
revascularization.
A special group of patients were women from the third 
trimester of pregnancy to one year after delivery. In this 
group of patients, the risk of adverse events was twice as 
high as in the general population and amounted to 20.6%, 
being also an important prognostic factor for 30-day adverse 
events (odds ratio [OR] 2.9). The Canadian SCAD study 
confirmed that SCAD is very important and often under-
-diagnosed condition, especially among young women. 
It seems that the conservative treatment strategy may 
be a better therapeutic option in this group of patients. 
Especially in young women diagnosed with myocardial 
infarction, spontaneous coronary dissection should be 
taken into account as the cause of myocardial infarction, 
which may affect the treatment strategy.
The MITRA-FR study, which aroused a lot of controversy, 
evaluated transcutaneous treatment of mitral regurgitation 
with MitraClip in patients with heart failure [3]. The study 
included patients with secondary severe mitral regurgita-
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ing subgroups of patients who can benefit from MitraClip 
device implantation.
The GLOBAL LEADERS trial is another very interesting 
study that can have an impact on everyday clinical practice. 
The study compared the use of ticagrelor in combination 
with acetylsalicylic acid (ASA) for 1 month, followed by 
ticagrelor alone vs conventional antiplatelet therapy in 
patients after PCI. The study included 16,000 patients with 
acute coronary syndrome or stable coronary artery disease 
who had a biolimus-eluting stent implanted. Patients were 
randomly assigned to one of three groups:
 — receiving ticagrelor and ASA for one month, followed by 
90 mg ticagrelor twice daily for 23 months;
 — receiving ASA and 75 mg clopidogrel once daily for 
12 months, followed by ASA monotherapy for another 
12 months (patients with stable coronary artery 
disease);
 — or receiving ASA and ticagrelor for 12 months, followed 
by ASA monotherapy for another 12 months (patients 
with acute coronary syndromes).
The composite primary endpoint assessed at 2 years 
included all-cause mortality and new Q-wave myocardial 
infarction. Secondary endpoints included major bleeding 
(according to the Bleeding Academic Research Consor-
tium criteria grade 3 or 5). At 2 years, 3.81% of patients 
receiving experimental therapy died or had myocardial 
infarction, compared with 4.37% of patients treated in 
accordance with the current standards of care (RR 0.87, 
95% CI 0.75–1.01, p = 0.073). Analysis of the subgroups 
of acute coronary syndrome and stable coronary artery 
disease did not confirm significant differences in the 
occurrence of the primary endpoint depending on the 
treatment strategy. There were no statistically significant 
between-group differences in major bleeding (2.04% of 
patients receiving experimental therapy vs 2.12% of pa-
tients receiving standard therapy). Interestingly, 12-month 
results confirmed that in patients after MI or PCI treated 
with ticagrelor, discontinuation of ASA after 1 month did 
not increase the frequency of composite endpoint com-
pared to dual antiplatelet therapy with clopidogrel and 
ASA. The study did not confirm improved prognosis in PCI 
patients treated with ticagrelor for 24 months compared to 
conventional 12-month therapy in combination with ASA. 
The lack of improvement may be caused by the fact that 
due to dyspnea, an adverse effect of ticagrelor therapy, 
and the frequent switching from ticagrelor to clopidogrel 
even in minor bleeding in the second year of observation, 
only 78% of patients took ticagrelor in the experimental 
group, while in the control group as many as 91.3% recei-
ved clopidogrel. Further studies with a very thorough as-
sessment of patients’ compliance with the dosing protocol 
are needed to establish whether discontinuation of ASA 
after 1 month of follow-up and therapy with one antiplate-
let agent in patient after PCI may be beneficial treatment 
strategy. Due to the above-mentioned limitations GLOBAL 
LEADERS did not provide a definitive answer, thereby being 
a negative research.
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